Talking Biotech with Dr. Kevin Folta

How do new drug applications move forward to approval? Four experts discuss the partnership between the FDA, the drug developer, and the data needed to move a product forward. It is a surprising discussion that reveals the depth of the FDA process. Joined by Dr. Debra Webster, Dr. Julia Marre, Dr. Michael Matthews and Dr. Jonathan Helfgott.

We live in amazing times of technological advance, but how are the real benefits of new tech lost to an inflated sense of risk? Dr. Felicia Wu from Michigan State University shares her expertise in describing the psychological basis of risk and applying it to questions like glyphosate and aspartame.

This is an update on the American Chestnut Restoration Project, as discussed previously on the podcast. The American Chestnut dominated the forests of Appalachia until an imported fungus destroyed the entire range. Efforts to restore the chestnut and its ecology have employed a biotechnology approach, integrating a gene from wheat that limits the mechanism the fungus uses to attack

Despite being over half of the population women's health care lags behind other areas of drug development. The problem is caused by many facets, but is augmented by the fact that many of the conditions are not life threatening or are functions of aging. Sabrina Johnson, CEO of Daré Bioscience, discusses how the disparity exists, the pipeline of drugs that seek to mitigate female-s

After a three month hiatus the Talking Biotech Podcast is back. Today's episode is a visit with Colarbra CEO Aoi Senju about his view for the podcast, followed by synopsis of three major news stories that broke since the last Talking Biotech Podcast. The new format includes a video component, and I'll be speaking with panels and also discussing recent news stories. It is an excitin

After 8.5 years of weekly podcasts I'm going to take a 5 week break and plan new episodes for 2024. I'm going through a medical glitch that has me unable to do my normal work. On top of this we're going to switch to an audio plus video format to find a wider audience. So check back in 2024 for the next episode. Have a great rest of 2023, thank you for listening, and looking forward

Even under the best conditions, crops need our assistance to survive the numerous threats that limit production. Classically, synthetic and natural compounds have been used to control insects, fungi and weeds, sometimes with negative collateral effects or fostering resistance of genetically tolerant genotypes. Todd Hauser from Trillium Ag describes his company's novel RNAi approach

There is tremendous variation in the plant kingdom, as plants have adapted to many ecological niches with discrete challenges. Part of adaptation is production of novel secondary metabolites, compounds not required for central metabolism that serve a role in the plant, such as defense or attraction of pollinators. The rainforest is replete with unusual plants and their resident met

Gene editing is a powerful and specific technique that allows customized changes to DNA. Because there are no additional sequences transferred, and alternations match what could happen naturally over time, the technology is considered less invasive and less prone to regulatory oversight. That's true in the USA, Canada, China and other nations. However, the European Court of Justice

Information has been weaponized, and the ability to create false information to achieve an ideological goal has never been more easy. Political polarization, science denial, and a shining, effective conduit of dissemination (the internet) allows anyone with an agenda to recruit the like minded, and produce compelling media to reinforce bankrupt ideas. Where did information warfare